The company’s recent engagements with the NYSCC signal a transition toward scientific validation of its core brands, including AESTURA and IOPE. At a June committee event, Jinseob Shin, Vice President of the Americas R&I Center, presented a split-face micro-needling study. Conducted alongside Dr. Jane Yoo of the Icahn School of Medicine at Mount Sinai, the research demonstrated how specific barrier-strengthening formulas accelerate skin recovery post-procedure, measuring concrete improvements in hydration and redness reduction.

Technical rigor also defined the company’s appearance at the NYSCC Suppliers' Day. Derma Science Director Michelle Shieh addressed the practical efficacy of emerging ingredients like PDRN and exosomes. The presentation highlighted a breakthrough in delivery systems, citing research published in ACS Nano that shows PDRN nano-liposomes achieving 7.8 times higher absorption rates than standard liposomes. This focus on proprietary delivery mechanisms and clinical outcomes serves as the primary engine for Amorepacific's strategy to capture the North American market, moving from aesthetic appeal to measurable dermatological performance.